We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Astellas Pharma is moving to extend patent protection for its enlarged-prostate treatment Flomax, a blockbuster drug that generated more than $1 billion in sales last year, the company said.
Ritalin manufacturer Celgene, and its distributor, Novartis, could experience major losses in revenue if they lose patent litigation in federal court to block a generic version of their attention-deficit/hyperactivity disorder (ADHD) treatment, according to Celgene.
A federal court has blocked plans by Mylan Laboratories to launch amlodipine besylate, a generic version of Pfizer’s blockbuster drug Norvasc, during the drug’s pediatric exclusivity period.
A little more than week after Ranbaxy Laboratories launched generic Lipitor in Denmark, Pfizer won a preliminary injunction blocking its sale, a Pfizer spokesman said.
With several pieces of legislation being considered to lower drug spending costs, lawmakers and industry sources see opportunities to overhaul federal healthcare policy to improve the generic drug industry.
Manufacturing methods used by Pfizer to produce its top-selling hypertension treatment drug Norvasc do not infringe on patents held by Synthon, a federal district court has ruled.
The U.S. Patent and Trademark Office rejected claims in a key patent covering Genentech’s respiratory treatment drug, Synagis, the company said, noting that it is contemplating challenging the decision.
The U.S. Patent and Trademark Office rejected claims in a key patent covering Genentech’s respiratory treatment drug, Synagis, the company said, noting that it is contemplating challenging the decision.
Japanese drug company Astellas Pharma held on to its remaining Flomax patent last week when a federal district court said generic tamsulosin hydrochloride infringes on the patent for its enlarged-prostate treatment, according to a company representative.
In a letter published in the Feb. 15 issue of the New England Journal of Medicine, molecular pathologist and attorney Roger Klein of the Yale University School of Medicine questioned the validity of patents used to prevent clinical laboratories from performing certain genetic tests.